BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 14.19B |
| Revenue (ttm) | 1.92B |
| Net Income (ttm) | 837.21M |
| Shares Out | 182.84M |
| EPS (ttm) | 4.40 |
| PE Ratio | 17.58 |
| Forward PE | 46.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,072,657 |
| Open | 77.26 |
| Previous Close | 77.76 |
| Day's Range | 76.84 - 78.69 |
| 52-Week Range | 71.65 - 92.57 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 110.83 (+43.2%) |
| Est. Earnings Date | Oct 28, 2021 |
About BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 110.83, which is an increase of 43.23% from the latest price.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. - BMRN
NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioMarin Pharmaceutical Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN).
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug
Stifel has upgraded BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) to Buy from Hold with a price target of $96, up from $86. After the stock's "significant underperformance" since August 2020, analyst Pau...
BioMarin (BMRN) Phenylketonuria Gene Therapy on Clinical Hold
BioMarin's (BMRN) phase I/II study on gene therapy candidate, BMN 307, has been placed under a clinical hold by the FDA possibly on malignancy concerns.
FDA Slaps Clinical Hold on BioMarin's Gene Therapy For Genetic Metabolism Disorder
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) faces another setback in its gene therapy development program after the FDA placed the phenylketonuria (PKU) gene therapy trial on hold. The Phase 1/2 Ph...
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim...
SAN RAFAEL, Calif., Sept. 6, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearl...
BioMarin's (BMRN) Dwarfism Drug Gets Approval in Europe
Biomarin Pharmaceutical's (BMRN) Voxzogo is the first medicine in Europe to be approved to treat achondroplasia, the most common form of dwarfism.
Why Is BioMarin (BMRN) Up 0.4% Since Last Earnings Report?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
Drug For Short-Limbed Dwarfism From Biomarin Wins European Approval
The European Commission (EC) has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) once-daily injection to treat achondroplasia. The approval covers children from 2 years until ...
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from ...
SAN RAFAEL, Calif., Aug. 27, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Commission (EC) has granted marketing authorization for VOXZOGO® (vosoriti...
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
SAN RAFAEL, Calif., Aug. 25, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual investor conferences.
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
All it will take is an FDA approval and a partial repeat of history.
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq produ...
BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 76.67% and 11.78%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Biomarin Pharmaceutical: Q2 Earnings Insights
Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 143.75% over the past year to $0.07, wh...
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
SAN RAFAEL, Calif., July 28, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 % C...
BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know
BioMarin (BMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin Shares 5-Year Data From Open-Label Trial Of Hemophilia Gene Therapy
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has announced new data from open-label Phase 1/2 trial of valoctocogene roxaparvovec, an investigational gene therapy candidate for severe hemophilia A. Data w...
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congr...
SAN RAFAEL, Calif., July 21, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adult...
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxap...
SAN RAFAEL, Calif., July 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment o...
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy
The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22
The European Medicines Agency (EMA) has validated BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) marketing application seeking approval for hemophilia A gene therapy, valoctocogene roxaparvovec. With toda...
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to ...
SAN RAFAEL, Calif., July 15, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization App...
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET
SAN RAFAEL, Calif., July 14, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a co...